| |
July 18-19, 2023 | Jersey City, NJ This is the only communications event for peer learning and networking exclusively for the life science community. Save $500, Register Today!
|
|
Today's Big NewsApr 5, 2023 |
|
Tuesday, April 11, 2023 | 12pm ET / 9am PT In this webinar we will guide you along the scientific data journey where you can discover smart ways to get from raw data to insights and how to achieve an automated, interconnected lab with data liquidity across the organization. Register now.
|
|
| By Max Bayer The FDA has approved 12 gene therapies so far, and the agency's top drug regulator wants to see the road ahead illuminated with green lights. |
|
|
|
By Fraiser Kansteiner For certain Bayer investors, the entry of a new CEO this summer could mean another shot at breaking up the German conglomerate. And for now, Roche veteran Bill Anderson, poised to take the throne from outgoing chief Werner Baumann in June, is keeping an “open mind.” |
By Annalee Armstrong Ginkgo Bioworks doesn’t want the biotech industry’s therapies. But it does want the platforms that create them, which is why the cell programming company is buying up StrideBio for its gene therapy platform. |
By Andrea Park Try as Philips might to forge a path out of its two-year-long saga of a slew of respiratory device recalls, the company is facing yet another—linked to more than 62,000 of its ventilators. |
|
Monday, April 24, 2023 | Boston, Massachusetts (and online) Intra-Target Microdosing (ITM) is a First-in-Human drug development approach that administers a drug microdose into a small target, generating therapeutic-level exposures in it and microdose exposures elsewhere, thus enabling collection of biomarkers. Join Us!
|
|
By Angus Liu,Eric Sagonowsky After already spending billions to defend itself against claims its talc products cause cancer, J&J is moving to end the litigation altogether. But lawyers for some plaintiffs have said the offer is "woefully inadequate." |
By Annalee Armstrong A new community-generated data resource from Pillar VC, the Founder-led Biotech Summit and compensation analysis firm Pave seeks to take the guesswork out of the process by summarizing salary ranges from 90 companies. |
By Andrea Park The recall affects just over 8,900 of the Hybrid and Rescue models of Getinge's Cardiosave balloon pumps, more than half of which were distributed in the U.S. |
By Annalee Armstrong NGM Bio’s webpage declares "We're Hiring!" but a peek at the investor relations section of the biotech’s website tells a different—and sobering—story. |
By Andrea Park Federal prosecutors are alleging that the trio of former leaders knew the tests provided incorrect results—and conspired to cover up those flaws—well before Magellan notified customers and regulators of the potential inaccuracies. |
By Max Bayer Proxygen has inked a third licensing deal in less than 30 months, singing on agreement with Merck & Co. worth more than $2.5 billion. The Austrian biotech is not disclosing how many targets the deal is for. |
By Zoey Becker,Angus Liu,Fraiser Kansteiner,Eric Sagonowsky,Kevin Dunleavy Gilead touted new findings on an oral antiviral. InflaRx's Gohibic won an authorization to treat critically ill COVID-19 patients. Plus more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
|
| Tuesday, April 11, 2023 | 1pm ET / 10am PT Achieving interoperability in healthcare can be a daunting task, but sharing and collaborating with data has the potential to generate better clinical outcomes, enable new care models, and enhance patient experience. Join healthcare industry experts for this important roundtable discussion to learn more. Register now. |
|
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
